Table 2 Comparison of clinical characteristics and laboratory data between the low serum FGF21 level group and high serum FGF21 level group in patients on HD
|  | Low FGF21 group ( FGF21 ≤ 184.50pg/ml ) | High FGF21 group ( FGF21>184.50pg/ml ) | P value |
|---|---|---|---|
Number | 170 | 169 | Â |
General data | |||
  Age(years) | 55.82 ± 15.60 | 57.76 ± 15.59 | 0.253 |
  Sex(male %) | 100(58.82 %) | 93(55.03 %) | 0.481 |
  Dialysis vintage(years) | 4.17 ± 4.45 | 4.49 ± 5.35 | 0.540 |
  Body mass index(BMI) | 22.93 ± 3.93 | 23.05 ± 4.09 | 0.794 |
  Systolic BP(mmHg) | 145.75 ± 24.91 | 145.82 ± 23.95 | 0.979 |
  Diastolic BP(mmHg) | 82.39 ± 13.95 | 82.25 ± 15.27 | 0.933 |
Blood data | |||
  Hemoglobin(g/L) | 99.92 ± 19.80 | 95.21 ± 20.07 | 0.031* |
  Albumin(g/L) | 36.80 ± 6.39 | 34.98 ± 5.74 | 0.006** |
  Uric acid(mmol/L) | 379.78 ± 134.65 | 377.50 ± 116.68 | 0.868 |
  Triglycerides(mmol/L) | 1.75 ± 1.39 | 1.88 ± 1.35 | 0.412 |
  Total cholesterol(mmol/L) | 4.19 ± 1.11 | 4.08 ± 1.13 | 0.346 |
  Dicarbonate(mmol/L) | 23.06 ± 3.74 | 22.24 ± 3.74 | 0.044* |
  Calcium(mmol/L) | 2.27 ± 0.24 | 2.26 ± 0.24 | 0.639 |
  Phosphate(mmol/L) | 1.73 ± 0.56 | 1.75 ± 0.61 | 0.744 |
  Parathormon(pg/ml) | 369.08 ± 452.80 | 379.08 ± 383.00 | 0.826 |
CT | |||
  L1 attenuation (HU) | 168.90 (137.75, 197.00) | 159.10 (118.15, 212.00) | 0.363 |
Comorbidity | |||
  Diabetes(%) | 60(35.29 %) | 50(29.59 %) | 0.262 |
  Hypertension(%) | 155(91.18 %) | 141(83.43 %) | 0.032* |
  CVD(%) | 43(25.29 %) | 34(20.12 %) | 0.255 |
Medicine usage | |||
  Vitamin D(%) | 76(44.71 %) | 75(44.38 %) | 0.952 |
  Calciu supplements(%) | 41(24.12 %) | 45(26.63 %) | 0.595 |
  Cinacalcet(%) | 31(18.24 %) | 21(12.43 %) | 0.138 |
  ACEI/ARB(%) | 52(30.59 %) | 42(24.85 %) | 0.238 |
FRAX(306) a | |||
  Major Osteoporosis | 3.78 ± 2.56 | 3.64 ± 2.70 | 0.637 |
  Hip fracture | 1.61 ± 1.85 | 1.57 ± 2.04 | 0.881 |